中国制造商进入柬埔寨的合规路线图

1. Key takeaway

For manufacturers outside Cambodia, the correct sequence is to settle classification and the local entity first, and discuss documentation only afterwards. If these two are not settled, however many pages are written, they will have to be redone. GRZAN recommends proceeding in the following six stages:

GRZAN note: of the six stages, the first 2 (classification and local entity) determine whether the following 4 have to be redone; the technical file is organised in 7 CSDT modules; foreign documents must be legalised at the Cambodian embassy or consulate in the country where the documents originate.

2. Regulatory basis

3. Expert commentary

1. What overseas manufacturers most often underestimate is consular legalisation. Section 2.3 of the DDF guideline expressly requires certification of translations at the Cambodian embassy or consulate nearest to the country where the documents originate. This makes notarisation and legalisation a strictly serial, non-parallel chain whose duration is outside the company’s control. It should be treated as a separate node on the critical path, not as an ”ancillary step of document preparation”.

1. Home-market registration certificates are ”valuable evidence” in Cambodia, not a ”free pass”. Cambodia has no recognition channel with any foreign regulator and no published rule naming reference authorities. Registration certificates and Certificates of Free Sale issued in the home market nevertheless remain important supporting evidence in the administrative and technical files, with real value for the clinical evidence section of Class B/C/D submissions.

1. The size of the Cambodian market must be weighed against the cost of access. Cambodia has a population of roughly 17 million (practical interpretation); the device market is import-driven, with public procurement and private hospitals coexisting. For product lines with many SKUs, ”no product grouping” materially raises the per-market cost — run a ”number of SKUs × cost per model” calculation at project approval before deciding whether to bring in the full range.

4. Practical recommendations

1. Produce written conclusions on ”classification + local entity” before starting dossier preparation. Each should become a controlled document forming the baseline for all subsequent work.
2. Run an economic calculation by SKU count and enter the market in batches where necessary. Register the core models first and add others after observing market response, avoiding deep one-off exposure under the ”no grouping” rule.
3. Write post-market obligations into the first contract. These include dual reporting of adverse events and FSCAs, retention of complaint and import/export records, and cooperation on advertising authorisation — obligations often overlooked at the quoting stage; retrofitting processes after an incident costs far more.

5. Verification checklist

• □ A/B/C/D classification completed and documented
• □ Route A or B chosen and the pharmacist’s credentials verified
• □ CamPORS account activated with a written record
• □ Dossier organised into the seven CSDT modules with all three channels ready
• □ Translation of foreign documents legalised at the Cambodian embassy or consulate in the country of origin
• □ Post-market obligations written into the first commercial contract

Regulatory information verified as of 29 October 2026.

In Southeast Asia, GRZAN’s core capabilities focus on three areas. First, tracking the legislative progress of dedicated medical device laws across member states — Singapore, Malaysia, Thailand, Indonesia, the Philippines and Vietnam have each established written device regulatory frameworks, whereas Cambodia still has no dedicated Medical Device Law. The current rules are assembled from three layers: the legal basis for registration numbers provided by the 1996 Law on the Management of Pharmaceuticals and its 2007 amendment, the classification and procedures provided by Prakas No. 1258 of 2012, and the technical framework of the ASEAN Medical Device Directive. Regulatory certainty is therefore markedly lower than in markets that have completed legislation. Second, local authorised representative services: GRZAN may act as the manufacturer’s statutory representative in Cambodia, carrying registration submissions, regulatory communication and post-market reporting obligations, and assisting with the practical implementation of the Cambodian registered pharmacist and pharmaceutical import/export enterprise licence requirements. Third, quality system and testing support: assisting with the establishment of a quality management system meeting ISO 13485 requirements, and organising the technical dossier in accordance with the ASEAN Common Submission Dossier Template (CSDT).

Business enquiries: info@grzanglobal.com